Integra LifeSciences Unveils New Real-World Evidence Highlighting PriMatrix Utilization
Integra LifeSciences will present new real-world data on its PriMatrix Dermal Scaffold at three major medical conferences in April, including analyses from nearly 1,000 cases across various wound types and a case series on burn injuries. The company emphasizes the product's role in complex reconstruction and limb salvage, adding to a growing body of evidence for its wound reconstruction portfolio. These presentations reinforce Integra's commitment to evidence-based solutions in advanced wound care.
Integra LifeSciences (NASDAQ: IART) posts 2025 loss and seeks approval of equity plan
Integra LifeSciences (NASDAQ: IART) is seeking stockholder approval for several proposals at its 2026 annual meeting, including the election of directors and an amendment to its equity incentive plan to increase available shares. The company reported a GAAP net loss of $516.5 million in 2025 despite a 1.5% increase in revenue to $1.64 billion, driven by significant investments in quality systems and infrastructure. The executive compensation program prioritizes pay-for-performance, with most executive compensation tied to company and individual performance goals, including annual organic revenue growth and, starting in 2026, adjusted EBITDA margin.
List of 16 Acquisitions by Integra LifeSciences (Apr 2026)
This article details Integra LifeSciences' acquisition history, highlighting 16 completed acquisitions. The company's acquisition strategy has focused primarily on the United States, with a concentration in Orthopedics, Regenerative Medicine, and Wound Care sectors. The most recent acquisition was Acclarent in December 2023 for $275M.
Vanguard disaggregates holdings; reports zero ownership in Integra (IART)
Vanguard has filed an amended Schedule 13G/A, reporting 0% ownership in Integra LifeSciences Holdings Corp (IART) following an internal realignment on January 12, 2026. This administrative change means Vanguard's subsidiaries will now report beneficial ownership separately, as per SEC Release No. 34-39538, and does not indicate a sale of shares but rather a change in reporting methodology. Investors seeking a full ownership picture should look for subsequent disaggregated filings from Vanguard's entities.
IART SEC Filings - Integra Lifesciences Hldgs Cp 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Integra LifeSciences Holdings Corporation's (IART) SEC filings, including 10-K, 10-Q, and 8-K forms, offering critical regulatory disclosures for investors. It features AI-powered summaries to help users understand complex financial reports, executive compensation structures, and governance matters. Recent filings detail financial results, goodwill impairment, insider trading activities, and changes to executive severance plans.
Integra (IART) CFO granted 111,179 RSUs; 8,089 shares withheld for tax
Integra LifeSciences Holdings Corp (IART) CFO Lea Daniels Knight was granted 111,179 restricted stock units (RSUs) which will vest over a three-year period. Concurrently, 8,089 shares were disposed of at $9.61 per share to cover tax obligations related to this equity grant. Following these transactions, Ms. Knight directly holds 50,489 common shares of Integra LifeSciences.
Integra (IART) CEO granted 343,393 restricted stock units as deferred pay
Integra LifeSciences Holdings Corp. President & CEO Poul Mojdeh was granted 343,393 restricted stock units (RSUs) as deferred compensation. These RSUs will vest in three equal annual installments starting March 11, 2026, and will be delivered as common stock after her separation from service. This grant brings her total reported RSU holdings to 445,691 units.
Integra (IART) EVP receives 92,108 RSUs and surrenders shares for taxes
Michael J. McBreen, EVP & President, CSS at Integra LifeSciences Holdings Corp (IART), was granted 92,108 restricted stock units (RSUs) with a three-year vesting schedule. To cover tax obligations, McBreen disposed of 2,354 and 7,247 common shares in tax-withholding transactions, not open-market sales. Following these transactions, he directly holds 60,743 common shares and the newly granted 92,108 RSUs.
Integra (NASDAQ: IART) EVP gets 43,350 RSUs, shares withheld for tax
Integra LifeSciences EVP Robert T. Davis Jr. received a grant of 43,350 restricted stock units (RSUs) on March 11, 2026, vesting over three years. To cover tax obligations related to this grant, 8,487 shares at $9.61 and 687 shares at $9.55 were withheld, totaling 9,174 shares. After these transactions, Davis directly holds 66,387 common shares and 43,350 RSUs, which are not open-market sales but tax-withholding transactions.
Integra Lifesciences (IART) EVP reports major RSU grant and vesting
Integra Lifesciences' EVP and President, International, Harvinder Singh, received a grant of 60,865 restricted stock units (RSUs) on March 11, 2026, which will vest over three years. Additionally, earlier RSU awards vested, leading to the conversion of 20,138 units into common stock, and 6,652 shares were withheld for tax obligations. After these transactions, Singh directly holds 21,690 shares of common stock, reflecting routine compensation activities rather than open-market trades.
Integra Lifesciences (IART) EVP gets 41,783 RSUs, 5,420 shares for tax
Integra Lifesciences' EVP & CHRO, Chantal Veillon-Berteloot, received 41,783 restricted stock units (RSUs) with a three-year vesting schedule. Simultaneously, 5,420 shares were disposed of at $9.61 per share to cover tax liabilities, a common practice for equity compensation. Following these transactions, Veillon-Berteloot directly owns 22,227 shares of common stock in the company.
Citigroup Maintains Sell Rating on IART and Lowers Price Target
Citigroup has maintained its "Sell" rating on Integra Lifesciences (IART) and lowered its price target from $11.00 to $9.00, an 18.18% decrease. This decision reflects a cautious outlook from Citigroup, aligning with a recent trend of declining price targets from other analysts. Despite this, the average one-year price target from 7 analysts suggests a potential upside of 63.86%, while GuruFocus estimates a significant upside of 186.13% based on its GF Value.
Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know
Shares of Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services dropped following a disappointing February jobs report that showed an unexpected contraction in employment, particularly in the healthcare sector. The report indicated a loss of 92,000 nonfarm payroll jobs and 28,000 positions in healthcare, raising concerns among investors about a potential economic slowdown and reduced demand for healthcare services. ICU Medical, in particular, saw a 3.9% decline, adding to its year-to-date losses, despite having a volatile stock performance over the past year.
Earnings call transcript: Integra LifeSciences beats Q4 2025 EPS forecast
Integra LifeSciences (IART) reported strong Q4 2025 earnings, surpassing EPS and revenue forecasts with adjusted EPS of $0.83 and revenue of $435 million. The company's stock rose 2.24% in premarket trading following the announcement, reflecting investor confidence despite challenging market conditions throughout the year. Integra provided 2026 guidance, expecting revenue between $1.66 billion and $1.7 billion, and adjusted EPS of $2.30 to $2.40.
Integra LifeSciences Opens Weak with 8.37% Gap Down Amid Market Concerns
Integra LifeSciences Holdings Corp. experienced a significant 8.37% gap down at market open, contributing to a 2.24% daily decline and a 1.82% monthly downturn, contrasting with the S&P 500's performance. The company, a small-cap player in the Pharmaceuticals & Biotechnology sector, has a market capitalization of USD 1,011 million, a P/E ratio of 9.00, and a debt-to-equity ratio of 1.52, with no dividend yield. Technical indicators, including moving averages, MACD, KST, and Bollinger Bands, reflect a bearish sentiment for the stock.
Integra LifeSciences Holdings Corp. Sees Revision in Stock Evaluation Amid Market Dynamics
Integra LifeSciences Holdings Corp. has experienced significant stock performance declines over the past year and three years, despite a modest monthly gain. The company's year-to-date results are unfavorable compared to the S&P 500, and technical indicators suggest a bearish sentiment. Investors will closely monitor its performance amidst these market challenges.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Consensus Recommendation of "Reduce" by Analysts
Integra LifeSciences Holdings Corporation (NASDAQ:IART) has received a consensus "Reduce" recommendation from seven research firms, with an average 12-month price target of $14.80. This comes despite the company slightly beating Q4 earnings and revenue estimates, as it still maintains a negative net margin and its FY2026 guidance is below analyst expectations. Institutional investors have actively traded the stock, with several hedge funds increasing their holdings.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q4 2025 Earnings Call Transcript
Integra LifeSciences reported Q4 2025 earnings, exceeding EPS expectations at $0.83 against a $0.79 forecast. The company outlined its strategic imperatives for 2026, focusing on strengthening quality, supply chain reliability, accelerating growth, and igniting innovation, while navigating tariff uncertainties and continuing remediation efforts for certain products like MediHoney. Despite some operational challenges and supply constraints impacting organic growth, the underlying demand for its products remains strong, with key products like SurgiMend expected to relaunch in Q4 2026.
Integra takes $511M hit from tariffs, quality and supply issues
Integra LifeSciences reported a significant Q4 and full-year 2025 financial performance, including a GAAP net loss of $(6.74) per share for the full year, primarily due to a $511 million goodwill impairment charge. The company attributed this impairment to a decline in share price reflecting external and operational factors like tariff changes, quality, operational, and supply-related challenges. Despite these setbacks and an organic revenue decline, Integra provided 2026 guidance expecting revenues between $1,662 million and $1,702 million and adjusted EPS of $2.30 to $2.40.
Integra LifeSciences (NASDAQ:IART) Surprises With Q4 CY2025 Sales
Integra LifeSciences (NASDAQ:IART) reported better-than-expected revenue and adjusted EPS for Q4 CY2025, with sales of $434.9 million and adjusted EPS of $0.83, surpassing analyst estimates. Despite the beat, revenue saw a 1.7% year-on-year decline, and Q1 CY2026 revenue guidance fell below expectations. The company's operating margin decreased significantly compared to the prior year, indicating rising expenses relative to revenue.
Goodwill hit drives 2025 loss at Integra LifeSciences (NASDAQ: IART)
Integra LifeSciences (NASDAQ: IART) reported a significant GAAP net loss of $(516.5) million for full-year 2025, primarily due to a $511 million goodwill impairment charge, despite a modest 1.5% increase in reported revenue to $1,635.2 million. The company's adjusted EPS declined to $2.23 from $2.56 in 2024, and free cash flow turned negative. For 2026, Integra LifeSciences projects revenue between $1,662 million and $1,702 million and adjusted EPS of $2.30 to $2.40, indicating a slight improvement over 2025.
Integra LifeSciences (IART) Stock Trades Down, Here Is Why
Integra LifeSciences (IART) shares fell 3.5% after the company issued a weak revenue forecast for the upcoming quarter and reported a significant drop in profitability, despite beating fourth-quarter revenue and adjusted earnings expectations. The medical device maker's first-quarter revenue guidance was below analyst estimates, and key metrics like operating margin and free cash flow showed deterioration, leading to investor sell-off. The stock has been volatile and is trading significantly below its 52-week high.
Integra LifeSciences Reports Q4 Loss, Revenue Edges Down
Integra LifeSciences Holdings Corporation (IART) reported a fourth-quarter loss of $1.70 million, or $0.02 per share, a significant drop from the $19.44 million profit in the prior year. Total revenue for the quarter slightly decreased by 1.7% to $434.93 million. The company provided full-year 2026 revenue guidance between $1.662 billion and $1.702 billion, with adjusted earnings per share projected at $2.30 to $2.40.
Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
Integra LifeSciences (IART) announced its financial results for Q4 and full-year 2025, reporting a revenue decrease of 1.7% in Q4 to $434.9 million and a full-year increase of 1.5% to $1,635.2 million. The company posted a GAAP net loss for both periods, primarily due to a significant goodwill impairment charge. Integra provided 2026 financial guidance, projecting revenues between $1,662 million and $1,702 million, alongside strategic initiatives for operational improvement.
Integra Lifesciences Holdings Q4 25 Earnings Conference Call At 8:30 AM ET
Integra Lifesciences Holdings Corp (IART) will host a conference call on February 26, 2026, at 8:30 AM ET to discuss its Q4 2025 earnings results. Interested parties can access the live webcast via the company's investor relations website. The article was written by RTTNews.com.
Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
Integra LifeSciences Holdings Corporation reported its fourth-quarter and full-year 2025 financial results, showing a decrease in revenues for Q4 2025 but an increase for the full year 2025 compared to 2024. The company announced a GAAP net loss for both periods, notably due to a significant goodwill impairment charge in 2025, and provided financial guidance for 2026, expecting revenue growth and adjusted earnings per share. Management highlighted operational progress in strengthening quality management systems and advancing its compliance master plan.
Integra LifeSciences (IART) Reports Earnings Tomorrow: What To Expect
Integra LifeSciences (IART) is set to report its earnings tomorrow morning, with analysts expecting a 2.7% year-on-year revenue decline, a reversal from the previous year's increase. The company has a history of missing Wall Street's revenue estimates and missed analysts' expectations last quarter. Investors will be watching closely after peers like Intuitive Surgical and Envista reported strong Q4 results.
Integra LifeSciences, Enovis, BrightSpring Health Services, IQVIA, and Charles River Laboratories Shares Plummet, What You Need To Know
Shares of Integra LifeSciences, Enovis, BrightSpring Health Services, IQVIA, and Charles River Laboratories plummeted after the Trump administration announced new global tariffs. This decision, invoking the Trade Act of 1974 to impose a 15% global tariff, created significant uncertainty for companies reliant on international supply chains. Investors are now assessing the potential impact on corporate earnings and broader economic activity.
Integra LifeSciences Announces Key Executive Leadership Appointments
Integra LifeSciences Holdings Corporation announced new executive appointments to strengthen its leadership team. Teshtar Elavia is appointed as the new Chief Technology Officer, a role created to advance R&D and innovation. Additionally, Michael Hutchinson joins as Chief Legal Officer and Kerri DiPietro as Chief Quality Officer, bringing extensive experience in legal, compliance, and quality management within the MedTech industry.
1 Russell 2000 Stock to Target This Week and 2 That Underwhelm
This article identifies one Russell 2000 stock, IonQ (IONQ), as a potential breakout candidate due to exceptional revenue growth and accelerating demand. Conversely, it highlights Integra LifeSciences (IART) and Fortrea (FTRE) as stocks likely to underperform, citing issues like slowing revenue growth, declining free cash flow margins, and high debt levels. The author stresses the importance of careful selection within the high-risk, high-reward Russell 2000 index.
Integra LifeSciences (IART) to Release Earnings on Thursday
Integra LifeSciences (NASDAQ: IART) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th. Analysts are forecasting earnings per share of $0.80 and revenue of $429.62 million. The stock currently has a "Reduce" consensus rating from analysts, with shares opening at $11.99 and institutional ownership standing at approximately 84.78%.
Integra LifeSciences appoints new CTO and key executives
Integra LifeSciences Holdings Corporation has appointed Teshtar Elavia as Chief Technology Officer, Michael Hutchinson as Chief Legal Officer, and Kerri DiPietro as Chief Quality Officer in a strategic move to bolster its leadership. These appointments aim to strengthen the innovative capabilities and operational improvements of the medical technology company, especially as it faces profitability challenges and scrutiny over its TruDi Navigation System. Despite recent stock declines, analysts anticipate a return to profitability for Integra LifeSciences.
Integra LifeSciences Announces Key Executive Leadership Appointments
Integra LifeSciences Holdings Corporation has announced key executive leadership appointments, including Teshtar Elavia as corporate vice president and chief technology officer, Michael Hutchinson as executive vice president, chief legal officer and secretary, and Kerri DiPietro as corporate vice president and chief quality officer. The creation of the CTO role emphasizes Integra's commitment to innovation and product development, while the other appointments strengthen the company's legal, compliance, ESG, and global quality functions. These strategic hires aim to drive the company's transformation and long-term value.
New tech and quality chiefs signal Integra’s next growth push
Integra LifeSciences (Nasdaq: IART) announced three key executive appointments aimed at driving future growth and innovation. Teshtar Elavia was named the first Chief Technology Officer, Michael Hutchinson as Executive Vice President and Chief Legal Officer, and Kerri DiPietro as Corporate Vice President and Chief Quality Officer. These appointments are expected to enhance the company's R&D, legal, compliance, and quality systems, building on recent positive regulatory and market developments.
Integra LifeSciences Announces Key Executive Leadership Appointments
Integra LifeSciences has announced key executive leadership appointments, including Teshtar Elavia as Chief Technology Officer, Michael Hutchinson as Chief Legal Officer, and Kerri DiPietro as Chief Quality Officer. These appointments aim to strengthen the company's innovation engine, legal and compliance functions, and global quality management system, reflecting a commitment to strategic growth and transformation.
Integra LifeSciences Announces Fourth Quarter and Full Year 2025 Financial Results Release Date and Conference Call Details
Integra LifeSciences Holdings Corporation announced it will release its fourth quarter and full year 2025 financial results on February 26, 2026, before the market opens, followed by a conference call at 8:30 a.m. ET. The company, a leader in medical technology, will webcast the call live on its investor website, encouraging participants to register for dial-in details in advance. This announcement highlights Integra's commitment to transparency and engagement with its stakeholders.
Global medical technology firm Integra LifeSciences sets Feb. 26 earnings call
Integra LifeSciences (NASDAQ: IART), a global medical technology company, will release its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, before market open. Management will host a conference call and live webcast at 8:30 a.m. ET to discuss the results. Historically, similar announcements have led to mild stock price movements, with investors now keenly awaiting detailed financial disclosures.
Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026
Integra LifeSciences Holdings Corporation announced it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, before the market opens. Following the release, the management team will host a conference call at 8:30 a.m. ET, with a live webcast available on the company's investor relations website. Interested participants can register to receive dial-in details for the event.
Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026
Integra LifeSciences Holdings Corporation announced it will release its fourth quarter and full year 2025 financial results on February 26, 2026, before the market open. Following the release, the management team will host a conference call at 8:30 a.m. ET, with a live webcast available on their investor relations website. Participants are encouraged to register in advance to receive dial-in details.
Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026
Integra LifeSciences Holdings Corporation will release its fourth quarter and full year 2025 financial results on February 26, 2026, before the market opens. Management will host a conference call at 8:30 a.m. ET, and a live webcast will be available on the company's investor relations website. A webcast replay will also be accessible after the call.
Investors in Integra LifeSciences Holdings (NASDAQ:IART) have unfortunately lost 84% over the last five years
Integra LifeSciences Holdings (NASDAQ:IART) shareholders have experienced an 84% loss over the past five years, with a 59% drop in the last year alone. Despite a decline in share price, the company's revenue has increased by 2.6% annually over the same five-year period, suggesting a disconnect between market sentiment and underlying business performance. Recent insider buying indicates a potential positive outlook for the company's future, urging investors to consider fundamental metrics alongside stock performance.
FDA Alert Targets Integra LifeSciences' MediHoney Wound Products
The FDA has issued an alert regarding Integra LifeSciences' MediHoney Wound products, clarifying that they are not associated with MediWound. Integra LifeSciences operates in the medical device sector, focusing on regenerative therapy and neurosurgical applications. The company faces financial challenges, including negative margins and high leverage, despite strong institutional interest and recent insider buying.
Integra LifeSciences Holdings C (IART) Stock Analysis: Navigating a 23.41% Potential Upside Amidst Challenges
Integra LifeSciences Holdings C (IART) shows a potential upside of 23.41% despite mixed financial performance, including positive revenue growth but negative EPS and ROE. The company, which operates in the medical devices industry, has strong free cash flow and reinvests earnings, facing varied analyst sentiment with an average target price of $15.50. Technical indicators suggest an overbought condition, emphasizing the need for investors to monitor sector trends and company developments closely.
Integra LifeSciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Integra LifeSciences Holdings Corporation announced that its CEO, Mojdeh Poul, and CFO, Lea Knight, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. ET. A live webcast of the presentation will be available on the company's investor relations website, providing broad access to their discussion on innovative treatment pathways in surgical, neurologic, and regenerative care. The company's participation highlights its standing in the medical technology sector and its commitment to engaging with investors.
Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference
Integra LifeSciences Holdings Corporation announced that CEO Mojdeh Poul and CFO Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. ET. A live webcast of their presentation will be available on the company's investor relations website. Integra LifeSciences is a global medical technology company focused on surgical, neurologic, and regenerative care.
Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference
Integra LifeSciences Holdings Corporation announced that its CEO, Mojdeh Poul, and CFO, Lea Knight, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will be available via live webcast on the company's investor relations website. Integra LifeSciences is a medical technology company focused on restoring patients' lives through innovative treatment pathways.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Consensus Rating of "Reduce" by Brokerages
Seven brokerages have issued a "Reduce" consensus rating for Integra LifeSciences Holdings Corporation (NASDAQ:IART), with an average 1-year price target of $15.00. This rating follows mixed quarterly results, where the company beat EPS expectations but missed revenue estimates and provided lower-than-analyst-expected Q4 and FY2025 guidance. Insider activity shows a director increasing their stake, while institutional investors hold a significant portion of the stock.
Is Integra LifeSciences (IART) Undervalued After Its Recent Share Price Rebound?
Integra LifeSciences (IART) has seen an 11% rebound recently, contrasting with a 40% year-down performance. Despite modest growth and losses, analysts suggest it is 15.5% undervalued with a fair value of $15.88, driven by strategic investments and cost optimization. The narrative emphasizes a potential future recovery and profit profile that could lead to double-digit upside.
Why Integra LifeSciences Holdings (IART) Is Up 17.7% After Medicare Expands Reimbursement for Skin Substitutes
Integra LifeSciences (IART) saw a 17.7% stock increase after Medicare expanded reimbursement for its skin substitute products, a move expected to boost patient access and commercial potential. This positive development supports the company's growth outlook, though ongoing operational risks from product recalls and manufacturing challenges remain concerns for investors. The company is projected to reach $1.9 billion in revenue and $90.9 million in earnings by 2028, with a fair value indicating a 21% upside.
Integra (NASDAQ: IART) gets FDA 510(k) for CUSA Clarity in cardiac surgery valve repair
Integra LifeSciences (Nasdaq:IART) has received FDA 510(k) clearance for its CUSA Clarity Ultrasonic Surgical Aspirator System for use in cardiac surgeries, specifically for debridement during valve replacement and repair. This expands the system's existing multi-specialty indications. The company plans to showcase CUSA Clarity at the AATS Mitral Valve Conclave in New York City on December 11–12, 2025.
